Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2018JAMA CardiologyOpen Access

Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

Stephen BurgessStephen BurgessBroad InstituteBFBrian A. FerencePreventive CardiologyJSJames R StaleyUniversity of Bristol

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Burgess et al. (2018) studied this question.

synapsesocial.com/papers/69d91a97ea2783c07da3c17ahttps://doi.org/10.1001/jamacardio.2018.1470
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk2017 · 330 citations
  2. 2Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations.1992 · 976 citations
  3. 3Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease2017 · 1,077 citations
  4. 4High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study2017 · 42 citations
  5. 5Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels2016 · 257 citations